RVNC Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Revance Therapeutics to Crown Laboratories We are investigating the fairness of the proposed sale of Revance Therapeutics to Crown Laboratories for $6.66 per share in cash.